Editing Metastatic Kidney Cancer (section)

===== CN followed by Targeted Therapy vs. Targeted Therapy alone =====

====== <span style="color:#ff00ff">CARMENA</span> (Clinical Trial to Assess the Importance of Nephrectomy) ======
* '''Population: 452 patients with metastatic ccRCC'''
** 44% had poor-risk disease, 56% had intermediate-risk
*** '''Trial does not apply to patients with favourable-risk'''
* '''<span style="color:#ff0000">Randomized to CN followed by sunitnib vs. sunitnib alone'''
* '''Primary outcome: OS'''
* '''Median follow-up 50.2 months'''
* '''<span style="color:#ff0000">Results'''
** '''<span style="color:#ff0000">OS: sunitinib alone was non-inferior to CN followed by sunitinib</span>''' (HR 0.89; 95% CI 0.71–1.10)
** '''No significant difference PFS or response to treatment'''
* [https://pubmed.ncbi.nlm.nih.gov/29860937/ Méjean, Arnaud, et al. "Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma." New England Journal of Medicine 379.5 (2018): 417-427.]